Search Results
50 Results for 'Vaccines'
PAGE 1 OF 2
Technology
SARS-COV-2 OMICRON BA.2 VARIANT FOR MEDICAL COUNTERMEASURE EVALUATION
UW-Madison researchers have isolated and characterized a BA.2 strain of the Omicron variant of SARS-CoV-2.
Learn More
Learn More
Yoshihiro Kawaoka | P220198US01
Technology
SARS-COV-2 BA.1 OMICRON VARIANT FOR MEDICAL COUNTERMEASURE EVALUATION
UW-Madison researchers have isolated and characterized a BA.1 strain of the Omicron variant of SARS-CoV-2.
Learn More
Learn More
Yoshihiro Kawaoka, Peter Halfmann | P220159US01
Technology
IDO Activity As A Marker Of Tumor Immune Escape And IDO Inhibitors As A Means Of Enhancing T Cells Response To Antigen Specific Vaccine
The present invention from UW Madison researchers provides compositions and methods of treating prostate cancer using a combination of a DNA vaccine, PD-1 inhibitor and an IDO inhibitor. Further, meth...
Learn More
Learn More
Douglas McNeel, Christopher Zahm, Laura Johnson | P190013US02
Technology
IDENTIFICATION OF SARS-COV-2 EPITOPES DISCRIMINATING COVID-19 INFECTION FROM CONTROL AND METHODS OF USE
UW – Madison researchers have determined that SARS-CoV-2 infection induces antibodies against both structural and non-structural proteins and they identified epitopes in the SARS-CoV-2 membrane ...
Learn More
Learn More
Irene Ong, David O'Connor, Miriam Shelef, Anna Heffron, David Baker, Maya Amjadi, Sean McIlwain, Saniya Khullar | P210048WO01
Technology
NEUTRALIZING VACCINES AGAINST HUMAN CORONAVIRUS
The present invention provides both QuilA-loaded chitosan (QAC)-encapsulated DNA vaccine compositions and viral vaccine compositions that encode a SARs-CoV-2 spike (S) protein, a SARs-CoV-2 nucleocaps...
Learn More
Learn More
Adel Talaat, Shaswath Chandrasekar | P210042US02
Technology
Recombinant Biologically Contained Filovirus Vaccine
The invention provides a vaccine comprising a recombinant biologically contained filovirus and methods of making and using those viruses.
Learn More
Learn More
Yoshihiro Kawaoka, Peter Halfmann | P180246US02
Technology
A novel vaccine with proven efficacy in preventing Francisella infections in fish.
The global food industry continues to search for sustainable fish protein sources. Increasingly, tilapia and other fish species have become the focus of healthy and sustainable farming methods. Howeve...
Learn More
Learn More
Matt Rogge, Benjamin LaFrentz, Esteban Soto, Khalid Shahin, Roshan Shrestha, Alvin Camus | T200057WO01
Technology
Generation of Wild Type and Mutant Ebola Virus from Cloned cDNA
Ebola Virus Disease (EVD) is a severe and highly fatal hemorrhagic fever that affects humans and other mammals. It is caused by the Ebola virus, a single-stranded RNA virus that encodes seven structur...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Luke Jasenosky | P01214US02
Technology
A ‘Humanized’ MDCK Cell Line For the Efficient Isolation and Amplification of Seasonal Human Influenza Viruses
Most influenza vaccines are produced in embryonated chicken eggs, but increasingly influenza vaccines are produced in other systems. MDCK (Madin-Darby Canine Kidney) cells are one of two mammalian cel...
Learn More
Learn More
Yoshihiro Kawaoka, Kosuke Takada, Masaki Imai | P180301US04
Technology
COVID-19 Vaccine
Provided herein are antigenic peptides comprising the SARS-CoV-2 spike protein receptor binding domain (CRBD) polypeptide or portions thereof, linked to a non-catalytic, nontoxic tetanus toxin varia...
Learn More
Learn More
Joseph Barbieri, Eric Johnson, Sabine Pellett, William Tepp, Amanda Przedpelski | P200268US03
Technology
RSV Virus-Like Particles And Methods Of Use Thereof
The present disclosure relates to vims-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial vims (RSV) infection. Specifically, the disclosure provides vi...
Learn More
Learn More
Elizabeth Wright, Larry Anderson, Binh Ha | P200021US02
Technology
Influenza M2 Protein Mutant Viruses As Influenza Live Attenuated Vaccines
A method to prepare recombinant influenza viruses comprising a mutant M2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well th...
Learn More
Learn More
Yoshihiro Kawaoka, Tokiko Watanabe | P07509US
Technology
Influenza Virus Replication For Vaccine Development
The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isola...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping | P150360US02
Technology
High Titer Recombinant Influenza Viruses With Enhanced Replication In Mdck Or Vero Cells Or Eggs
The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isola...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping | P130287US02
Technology
Influenza Virus Replication By Inhibiting Microrna Lec7c Binding To Influenza Viral Crna And Mrna
A vector, composition and method to improve influenza virus replication by inhibiting miRNA lec-7C binding to influenza virus mRNA and/or cRNA.
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping | P150345US02
Technology
Generation Of Infectious Influenza Viruses From Virus-Like Particles
Compositions and methods to prepare influenza virus-like particles (VLPs) are provided.
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann | P150373US02
Technology
Vaccines Comprising Mutant Attenuated Influenza Viruses
The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant ...
Learn More
Learn More
Yoshihiro Kawaoka, Shinji Watanabe, Tokiko Watanabe | P100251US02
Technology
Recombinant Influenza Viruses With Stabilized Ha For Replication In Eggs
Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus...
Learn More
Learn More
Yoshihiro Kawaoka, Shinya Yamada, Shiho Chiba | P200038US02
Technology
Vectors For Eliciting Immune Responses To Non-Dominant Epitopes In The Hemagglutinin (Ha) Protein
Methods of preparing influenza viruses having altered immunodominant epitopes in HA, e.g., having one or more residues in one or more of antigenic sites A-E in HA altered, and viral vectors, e.g., inf...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Huihui Kong | P190028US02
Technology
Humanized Cell Line
A mammalian or avian cell line that expresses high levels of human influenza virus receptors is provided. In one embodiment, the cell line supports human influenza virus, e.g., human A/H3 influenza vi...
Learn More
Learn More
Yoshihiro Kawaoka, Kosuke Takada, Masaki Imai | P180301US03
Technology
Novel Adjuvant For Animal And Human Vaccines
Quil-A chitosan spherical nanostructure complexes as well as methods of making and using such complexes are disclosed herein. Also provided are Quil-A chitosan spherical nanostrucutres loaded with one...
Learn More
Learn More
Adel Talaat, Shaswath Chandrasekar | P190189US02
Technology
Recombinant Influenza Viruses With Stabilized Ha For Replication In Eggs
Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus ...
Learn More
Learn More
Yoshihiro Kawaoka, Shinya Yamada, Shiho Chiba | P180114US03
Technology
Improved Influenza Virus Replication For Vaccine Development
An isolated recombinant influenza virus is provided having PA, PB1, PB2, NP, NS, M, NA and HA viral segments, wherein the PB1 viral segment encodes a PB1 with a residue other than isoleucine at positi...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping | P190171US02
Technology
Modified Clostridial Neurotoxins As Vaccines And Conjugate Vaccine Platforms
Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more ...
Learn More
Learn More
Eric Johnson, Sabine Pellett, William Tepp, Joseph Barbieri, Amanda Przedpelski | P190179US02
Technology
Mutations That Confer Genetic Stability To Additional Genes In Influenza Viruses
The disclosure provides for an isolated recombinant influenza virus having at least one of: a PB2 viral segment encoding PB2 with residue at position 540 that is not asparagine or a residue at positio...
Learn More
Learn More
Yoshihiro Kawaoka, Yuri Furusawa | P190174US02